

NEW USES OF WESTPHAL CONDENSATION: SYNTHESIS OF FLAVOCORYLENE AND RELATED INDOLO[2,3-a]QUINOLIZINIUM SALTS.


María P. Matia^a, Jesús Ezquerro^b, José L. García-Navío^a,
Juan J. Vaquero^a and Julio Alvarez-Builla^{*a}.

^a Departamento de Química Orgánica, Universidad de
Alcalá, 28871 Alcalá de Henares, Madrid (Spain)

^b Centro de Investigación LILLY S.A., Paraje de la Cruz
s/n, 28130 Valdeolmos, Madrid (Spain)

Abstract: Using the Westphal condensation, flavocorylene and related Indolo[2,3-a]-quinolizinium salts have been prepared in two steps, starting from commercially available β -carboline derivatives.


The small group of biogenetically-interesting¹ indole alkaloids that incorporate the zwitterionic indolo[2,3-a]quinolizinium ring system **I** has received limited attention in the synthesis field.² Some of its representatives such as flavopereirine (**1**) and sempervirine (**2**) have been described to possess antitumour activity,³ but the relatively complex preparation methods has reduced the availability of analogs.



R₁=Et R₂=H
R₁-R₂=(CH₂)_n-

Our interest in the Westphal condensation⁴ as an easy way to prepare quinolizinium salts⁵ led us to exploit the reactivity of 9H-2-ethoxycarbonylmethyl-1-methylpyrido[3,4-b]indolium bromides **4** and **5**, which were prepared in high yields from commercially available β -carbolines harmine and harmine.⁶

Basic condensation of both salts with symmetric 1,2-diketones, such as 3,4-hexanedione and 1,2-acenaphthenequinone, provided the 12H-indolo[2,3-a]quinolizinium bromides⁷ **8a,b** and **9a,b**. Anion exchange of bromide (**8a**, X=Br) produced the already described Flavocorylene hydrochloride⁸.



Compound	R'	Z	X	R	R	Yield(%)
8a	H	CH	Br	CH ₃ CH ₂	CH ₃ CH ₂	60
8b	H	CCO ₂ Et	Br	1,8-Naphthalenediyl		94
9a	OCH ₃	CH	Br	CH ₃ CH ₂	CH ₃ CH ₂	50
9b	OCH ₃	CCO ₂ Et	Br	1,8-Naphthalenediyl		70
10b	H	N	MSTS*	1,8-Naphthalenediyl		73
10c	H	N	MSTS	Diphen- <i>o,o'</i> -diyl		84
11b	OCH ₃	N	MSTS	1,8-Naphthalenediyl		75
11c	H	N	MSTS	Diphen- <i>o,o'</i> -diyl		70

* Mesitylenesulfonate

Our methodology is equally applicable to the synthesis of the new 12H-pyridazino[2':3',1,2]pyrido[3,4-b]indolium mesitylenesulfonates **10b,c** and **11b,c** isoelectronic with the bromides **8** and **9**, by a modified Westphal condensation, recently developed by us.⁹ Thus, amination with O-mesitylenesulfonyl-hydroxylamine (MSH)¹⁰ of the starting harmine and harmine precursors yielded the corresponding 2-amino-1-methyl-9H-pyrido[3,4-b]-indolium mesitylenesulfonates **6** and **7** (X=MSTS) which, in basic conditions⁸, reacted with 1,2-acenaphthenequinone and 9,10-phenanthrenequinone yielding the new salts **10** and **11** (X=MSTS).

Further experiments are in progress to extend this methodology to other 1,2-dicarbonyl compounds as asymmetric diketones and 1,2-ketoaldehydes.

In summary, the new approach represents a straightforward preparation of 12H-indolo[2,3-a]-quinolizinium derivatives which can be easily extended to new biologically interesting compounds.

References and notes.

- (a) Scott, A.I. *Bioorg. Chem.* **1974**, *3*, 398; (b) Kan-Fan, C; Husson, H.-P. *Tetrahedron Lett.* **1980**, *21*, 4265.
- For recent synthetic efforts and references to the isolation of these alkaloids, see a) Teuber, H.-J.; Quintanilla-Licea, R; Raabe, T. *Liebigs Ann. Chem.* **1988**, 1111; (b) Gribble, G.W.; Johnson, D.A. *Tetrahedron Lett.* **1987**, *44*, 5259; c) Ninomiya, I.; Tada, Y.; Kiguchi, T; Yamamoto, O.; Naito, T. *J. Chem. Soc. Perkin Trans. 1* **1984**, 2035; d) Giri, V.S.; Maiti, B.C.; Pakrashi, S.C. *Heterocycles* **1984**, *22*, 233.
- (a) Beljanski, M; Beljanki, M.S. *Expl. Cell Biol.* **1982**, *50*, 79; (b) Beljanski, M; Beljanki, M.S. *Oncology.* **1986**, *43*, 198.
- Westphal, O.; Jahn, K.; Heffe, W. *Arch. Pharm.* **1961**, *294*, 37.
- Matia, M.P.; Sanchez-Ferrando, F; Ezquerria, J; Garcia-Navio, J.L.; Vaquero, J.J.; Alvarez-Builla, J. *Tetrahedron.* **1991**, *47*, 0000.
- ¹H NMR spectra were recorded on a Varian Unity 300 instrument. Chemical shifts are expressed in parts per million downfield from tetramethylsilane. The proton resonances for the mesitylenesulfonate anion in **6**, **7**, **10b,c** and **11b,c** have not been listed as they are independent of the heterocyclic cation, signals appearing in all cases at 6.62 ppm for the aromatic protons and 2.44 and 2.15 ppm for the ortho and para methyl groups, respectively. Satisfactory microanalyses were obtained for all new compounds described, within 0.4% error.
- Typical procedure: Equivalent amounts (10 mmol) of the corresponding heterocyclic precursor and ethyl bromoacetate in dry acetone (30 ml) were refluxed for 4 hours. The precipitate was collected and recrystallized from ethanol.
Compound **4**. (250-252°C, 90%) ¹H NMR(DMSO-d₆) δ 13.00 (s, 1H, NH), 8.75 (d, 1H, J=6.6 Hz, H-3), 8.60 (d, 1H, J=6.6 Hz, H-4), 8.45 (d, 1H, J=8.0 Hz, H-5), 7.85-7.75 (m, 2H, H-7 and H-8), 7.5-7.4 (m, 1H, H-6), 5.81 (s, 2H, CH₂CO), 4.25 (q, 2H, J=7.1 Hz, -CH₂CH₃), 3.04 (s, 3H, CH₃-C1), 1.25 (t, 3H, J=7.1 Hz, CH₂CH₃). (Found: C, 55.10; H, 5.15; N, 7.95. C₁₆H₁₇BrN₂O₂ requires C, 55.02; H, 4.91; N, 8.02).
Compound **5**. (223-225°C, 80%) ¹H NMR(DMSO-d₆) δ 12.82 (s, 1H, NH), 8.6-8.5 (m, 2H, H-3 and H-4), 8.31 (d, 1H, J=8.7 Hz, H-5), 7.13 (d, 1H, J=1.9 Hz, H-8), 7.06 (dd, 1H, J=8.8 and 1.9 Hz, H-6), 5.72 (s, 2H, -CH₂CO-), 4.24 (q, 2H, J=7.1 Hz, -CH₂CH₃), 3.94 (s, 3H, -OCH₃), 2.98 (s, 3H, CH₃-C1), 1.26 (t, 3H, J=7.1 Hz, CH₂CH₃). (Found: C, 53.70; H, 5.20; N, 7.55. C₁₇H₁₉BrN₂O₃ requires C, 53.83; H, 5.05; N, 7.39).
- General Procedure: Equivalent amounts (10 mmol) of the azinium salts **4-7**, the dicarbonyl derivative, and anhydrous sodium acetate (0.82 g, 10 mmol) were suspended in dry acetone (10 ml). The mixture was refluxed for 2 h. The precipitate was filtered. Crystallization from the acetic acid/acetone yielded the compounds **8-11** in analytical grade. All melted above 260°C.
8a. ¹H NMR(CD₃OD) δ 9.05 (s, 1H, H-4), 8.81 (d, 1H, J=7.0 Hz, H-6), 8.63 (s, 1H, H-1), 8.55 (d, 1H, J=7.0 Hz, H-7), 8.32 (d, 1H, J=8.0 Hz, H-8), 7.8-7.65 (m, 2H, H-10 and H-11), 7.45 (bt, 1H, H-9), 3.09 (q, 2H, J=7.3 Hz, CH₂-C2), 2.99 (q, 2H, J=7.3 Hz, CH₂-C3), 1.55 (t, 3H, J=7.3 Hz, CH₃-CH₂-C2), 1.46 (t, 3H, J=7.3 Hz, CH₃-CH₂-C3). (Found: C, 64.13; H, 5.49; N, 7.65. C₁₉H₁₉BrN₂ requires C, 64.23; H, 5.39; N, 7.89).
8b. ¹H NMR(CF₃COOD) δ 8.91 (s, 1H, H-1), 8.3-8.15 (m, 3H), 7.9-7.75 (m, 6H), 7.5-7.3 (m, 3H), 5.20 (q, 2H, J=7.1 Hz, -CH₂CO), 1.92 (t, 3H, J=7.0 Hz, CH₃CH₂). (Found: C, 68.00; H, 3.85; N, 5.70. C₂₈H₁₉BrN₂O₂ requires C, 67.89; H, 3.87; N, 5.66).
9a. ¹H NMR(CD₃OD) δ 8.95 (s, 1H, H-4), 8.76 (d, 1H, J=6.9 Hz, H-6), 8.52 (s, 1H, H-1), 8.43 (d, 1H, J=6.9 Hz, H-7), 8.16 (d, 1H, J=8.8 Hz, H-8), 7.20 (d, 1H, J=2.2 Hz, H-11), 7.06 (dd, 1H, J= 8.7 and 2.2 Hz, H-9), 3.97 (s, 3H, OCH₃), 3.06 (q, 2H, J=7.3 Hz, CH₂-C2), 2.98 (q, 2H, J=7.3 Hz, CH₂-C3), 1.54 (t, 3H, J=7.3 Hz, CH₃-CH₂-C2), 1.44 (t, 3H, J=7.3 Hz, CH₃-CH₂-C3). (Found: C, 62.15; H, 5.30; N, 7.45. C₂₀H₂₁BrN₂O requires C, 62.34; H, 5.49; N, 7.27).

Figure 1. Optimized geometry and atomic charges for the peptide bond (a), the transition-state (b), 9(CH₃CN₂) (c) and 9(CH₃NH) (d).

- 9b. $^1\text{H NMR}(\text{CF}_3\text{COOD})$ δ 9.12 (s, 1H, H-1), 8.6-8.5 (m, 2H), 8.29 (d, 1H, $J=7.1$ Hz, H-7), 8.2-8.1 (m, 2H), 8.01 (d, 1H, $J=6.9$ Hz), 7.9-7.7 (m, 4H), 6.95 (bd, 1H, H-9), 5.28 (q, 2H, $J=7.1$ Hz, $-\text{CH}_2\text{CO}$), 3.94 (s, 3H, OCH_3), 1.94 (t, 3H, $J=7.0$ Hz, CH_3CH_2). (Found: C, 66.15; H, 4.10; N, 5.25. $\text{C}_{29}\text{H}_{21}\text{BrN}_2\text{O}_3$ requires C, 66.29; H, 4.03; N, 5.33).
- 10b. $^1\text{H NMR}(\text{CF}_3\text{COOD})$ δ 9.12(s, 1H, H-1), 8.97 (d, 1H, $J=7.1$ Hz, H-6), 8.42 (d, 1H, $J=7.1$ Hz), 8.37 (d, 1H, $J=7.1$ Hz, H-7), 8.30 (d, 1H, $J=6.8$ Hz), 8.15-8.05 (m, 3H, H-8 and 2H from the acenaphthene moiety), 7.90 (t, 1H, $J=7.5$ Hz), 7.83 (t, 1H, $J=7.3$ Hz), 7.7-7.65 (m, 2H, H-10 and H-11), 7.39 (t, 1H, $J=6.8$ Hz, H-9). (Found: C, 72.70; H, 4.50; N, 7.55. $\text{C}_{33}\text{H}_{25}\text{N}_3\text{O}_3\text{S}$ requires C, 72.91; H, 4.64; N, 7.73).
- 10c. $^1\text{H NMR}(\text{CF}_3\text{COOD})$ δ 9.67 (s, 1H, H-1), 8.97 (d, 1H, $J=7.0$ Hz, H-6), 8.93 (d, 1H, $J=7.1$ Hz), 8.54 (d, 1H, $J=7.1$ Hz), 8.46 (d, 1H, $J=7.0$ Hz, H-7), 8.29 (d, 2H, $J=7.1$ Hz), 8.14 (d, 1H, $J=7.2$ Hz, H-8), 7.81 (t, 1H, $J=7.2$ Hz), 7.75-7.6 (m, 5H, H-10, H-11 and 3H from the phenanthrene moiety), 7.44 (t, 1H, $J=6.8$ Hz, H-9). (Found: C, 73.50; H, 4.65; N, 7.20. $\text{C}_{35}\text{H}_{27}\text{N}_3\text{O}_3\text{S}$ requires C, 73.79; H, 4.78; N, 7.38).
- 11b. $^1\text{H NMR}(\text{CF}_3\text{COOD})$ δ 9.13 (s, 1H, H-1), 9.03 (d, 1H, $J=7.1$ Hz, H-6), 8.49 (d, 1H, $J=7.1$ Hz, H-7), 8.37 (d, 1H, $J=6.8$ Hz, 2H), 8.24 (d, 1H, $J=8.3$ Hz), 8.19 (d, 1H, $J=8.5$ Hz), 8.09 (d, 1H, $J=9.0$ Hz, H-8), 8.0-7.9 (m, 2H), 7.23 (s, 1H, H-11), 7.09 (d, 1H, $J=8.9$ Hz, H-9), 3.99 (s, 3H, OCH_3). (Found: C, 71.20; H, 4.50; N, 7.60. $\text{C}_{34}\text{H}_{27}\text{N}_3\text{O}_4\text{S}$ requires C, 71.18; H, 4.74; N, 7.33).
- 11c. $^1\text{H NMR}(\text{CF}_3\text{COOD})$ δ 9.42 (s, 1H, H-1), 8.9-8.8 (m, 2H), 8.47 (d, 1H, $J=7.5$ Hz), 8.3-8.2 (m, 3H), 7.9-7.7 (m, 5H), 7.0-6.9 (m, 2H, H-9 and H-11), 3.85 (s, 3H, OCH_3). (Found: C, 71.95; H, 4.90; N, 6.85. $\text{C}_{36}\text{H}_{29}\text{N}_3\text{O}_4\text{S}$ requires C, 72.10; H, 4.87; N, 7.01).
8. Prasad, K. B.; Swan G. A. *J. Chem. Soc.* **1958**, 2024.
9. Matia, M.P.; García-Navio, J.L.; Vaquero, J.J.; Alvarez-Builla, J. *J. Heterocyclic Chem.* **1990**, *27*, 661.
10. **Standard procedure:** To a stirred solution of *O*-mesitylenesulfonylhydroxylamine (MSH) (2.15 g, 10 mmol) in dichloromethane (20 ml), the corresponding azine (10 mmol) in the same solvent (20 ml) was dropwise added. The mixture was stirred at room temperature for 10 min. Diethyl ether (30 ml) was then added to precipitate the *N*-aminoazinium salts **6** and **7** which were triturated with ether (3x5 ml) and recrystallized from ethanol.
6. (217-219°C, 92%) $^1\text{H NMR}(\text{CD}_3\text{OD})$ δ 8.44 (d, 1H, $J=6.7$ Hz, H-3), 8.37 (d, 1H, $J=6.8$ Hz, H-4), 8.30 (d, 1H, $J=8.1$ Hz, H-5), 7.8-7.7 (m, 2H, H-7 and H-8), 7.5-7.4 (m, 1H, H-6), 3.09 (s, 3H, $\text{CH}_3\text{-C1}$). (Found: C, 63.25; H, 5.90; N, 10.77. $\text{C}_{21}\text{H}_{23}\text{N}_3\text{O}_3\text{S}$ requires C, 63.45; H, 5.83; N, 10.57).
7. (234-236°C, 87%) $^1\text{H NMR}(\text{DMSO-}d_6)$ δ 12.60 (s, 1H, NH), 8.46 (d, 1H, $J=6.9$ Hz, H-3), 8.36 (d, 1H, $J=6.9$ Hz, H-4), 8.26 (d, 1H, $J=8.5$ Hz, H-5), 7.65 (s, 2H, NH_2), 7.10 (d, 1H, $J=2.0$ Hz, H-8), 7.01 (dd, 1H, $J=8.4$ and 1.9 Hz, H-6), 3.91 (s, 3H, OCH_3), 2.97 (s, 3H, $\text{CH}_3\text{-C1}$). (Found: C, 62.00; H, 5.70; N, 9.80. $\text{C}_{22}\text{H}_{25}\text{N}_3\text{O}_4\text{S}$ requires C, 61.80; H, 5.89; N, 9.83).
11. Authors wish to acknowledge the assistance provided by LILLY S.A. for the Nmr analysis, and to the Comisión Interministerial de Ciencia y Tecnología (CICYT) for financial support (Project PB87-0755).

(Received in UK 14 October 1991)